Comparing PetIQ (PETQ) and AmerisourceBergen (ABC)
PetIQ (NASDAQ: PETQ) and AmerisourceBergen (NYSE:ABC) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.
Institutional & Insider Ownership
37.0% of PetIQ shares are held by institutional investors. Comparatively, 66.9% of AmerisourceBergen shares are held by institutional investors. 27.3% of AmerisourceBergen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares PetIQ and AmerisourceBergen’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|PetIQ||$266.69 million||2.02||-$3.49 million||$0.39||59.00|
|AmerisourceBergen||$153.14 billion||0.13||$364.48 million||$5.88||15.28|
AmerisourceBergen has higher revenue and earnings than PetIQ. AmerisourceBergen is trading at a lower price-to-earnings ratio than PetIQ, indicating that it is currently the more affordable of the two stocks.
This table compares PetIQ and AmerisourceBergen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
AmerisourceBergen pays an annual dividend of $1.52 per share and has a dividend yield of 1.7%. PetIQ does not pay a dividend. AmerisourceBergen pays out 25.9% of its earnings in the form of a dividend. AmerisourceBergen has raised its dividend for 13 consecutive years.
This is a breakdown of recent ratings and price targets for PetIQ and AmerisourceBergen, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
PetIQ presently has a consensus target price of $28.20, suggesting a potential upside of 22.56%. AmerisourceBergen has a consensus target price of $103.07, suggesting a potential upside of 14.69%. Given PetIQ’s stronger consensus rating and higher probable upside, equities analysts plainly believe PetIQ is more favorable than AmerisourceBergen.
AmerisourceBergen beats PetIQ on 11 of the 16 factors compared between the two stocks.
PetIQ, Inc. develops, manufactures, and distributes pet medications, and health and wellness products for dogs and cats in the United States, Canada, and Europe. It offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements. The company provides its products primarily under the VetIQ, PetAction Plus, Advecta, PetLock Plus, and TruProfen brands. It sells its products through distributors as well as through retail stores, including approximately 40,000 retail pharmacy locations. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment provides pharmaceutical distribution and other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers. The company's Other segment provides commercialization support services, including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers; specialty transportation and logistics services for the biopharmaceutical industry; and animal health care products. It markets its products and services through independent sales forces and marketing organizations. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.